Who is sponsoring NCT05979662?

NCT05979662 is sponsored by Ibrahim Talal Elshamy.

What drugs are being tested in NCT05979662?

Interventions in NCT05979662: Endoscopic frontal sinus surgery grade 6(Draf III)., Endoscopic frontal sinus surgery grade 1-3(Draf I or IIa).

What condition does NCT05979662 study?

NCT05979662 studies Endoscopic Frontal Sinus Surgery, Chronic Rhinosinusitis With Nasal Polyps, Draf III, Draf I or IIa.

Is NCT05979662 still recruiting?

NCT05979662 is currently status unknown. Last updated 7 August 2023.

Last reviewed 2023-08-07 · How we verify

NCT05979662

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endoscopic Frontal Sinus Surgery Draf III in Moderate to Severe Eosinophilic Chronic Rhinosinusitis With Polyps

Status unknown NA Last updated 7 August 2023

What this trial tests

NA trial testing Endoscopic frontal sinus surgery grade 6(Draf III). in Endoscopic Frontal Sinus Surgery in 50 participants. Status unknown.

Timeline

1 January 2021

Primary endpoint
30 September 2023

30 September 2023

Quick facts

Lead sponsor	Ibrahim Talal Elshamy
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	50
Start date	1 January 2021
Primary completion	30 September 2023
Estimated completion	30 September 2023
Sites	2 locations across Egypt

Drugs / interventions tested

Endoscopic frontal sinus surgery grade 6(Draf III).
Endoscopic frontal sinus surgery grade 1-3(Draf I or IIa)

Conditions studied

Endoscopic Frontal Sinus Surgery — all drugs for Endoscopic Frontal Sinus Surgery →
Chronic Rhinosinusitis With Nasal Polyps — all drugs for Chronic Rhinosinusitis With Nasal Polyps →
Draf III — all drugs for Draf III →
Draf I or IIa — all drugs for Draf I or IIa →

Sponsor

Ibrahim Talal Elshamy

Who can join

18 and older, any sex, with Endoscopic Frontal Sinus Surgery or Chronic Rhinosinusitis With Nasal Polyps. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the effect of the primary endoscopic frontal sinus surgery on the clinical outcome in patients having moderate to severe eosinophilic chronic rhinosinusitis with polyps with primary outcome measures in form of recurrence of polyp using endoscopic polyp score and Secondary outcome measures include Lund MacKay score, SNOT-22 and need for corticosteroid to control polyp postoperatively.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05979662 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ibrahim Talal Elshamy
Last refreshed: 7 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05979662.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing